1. Introduction {#S1}
===============

Bis-retinoid *N*-retinyl-*N*-retinylidene ethanolamine (A2E) accumulation in the retinal pigmented epithelial (RPE) cells is a hallmark of Stargardt disease, a juvenile form of macular degeneration, caused by ABCA4 mutations ([@R5], [@R60], [@R3], [@R91]). Age-related A2E accumulation and over-accumulation of A2E in patients with age-related macular degeneration (AMD) have also been reported ([@R60], [@R25], [@R66], [@R41], [@R4]). Roles of accumulation of A2E in RPE cells in these retinal degenerative diseases have been long under investigation. A2E is one byproduct of the visual cycle, which is a recycling mechanism of the visual chromophore 11-*cis*-retinal. A2E formation occurs through the condensation of two all-*trans*-retinal molecules and phosphatidylethanolamine ([@R94], [@R52], [@R57]). In vertebrate vision, photoisomerization of 11-*cis*-retinal to all-*trans*-retinal activates photoreceptor G-protein coupled receptor, rhodopsin, and the light signal is converted to electrical signals which relay visual stimuli to the brain ([@R65]). Clearance of all-*trans*-retinal from photoreceptors is quickly performed under healthy conditions, but any delay of this reaction can lead to an increased concentration and condensation of all-*trans*-retinal to form byproducts including A2E and all-*trans*-retinal dimer (RALdi) in the RPE ([@R58], [@R20]). RPE cell death was observed by photooxidation of A2E due to generation of singlet oxygen and superoxide radicals ([@R87]). Other studies demonstrated that A2E can cause retinal inflammation which leads to retinal cell damage ([@R8], [@R71], [@R103]). A2E could play an important role in the pathogenesis of retinal degeneration; however, *Abca4*^−/\ −^ mice which accumulate high levels of A2E display a very mild phenotype suggesting a minor role of this molecule in mouse models of retinal degeneration ([@R97]).

Oxidative stress is another important contributing environmental factor to the development of retinal diseases including AMD ([@R42], [@R62]). Anti-oxidative enzymes in RPE cells decrease with age, potentially allowing reactive oxygen species (ROS) generated to cause DNA damage and ultimately leading to the apoptosis of RPE cells ([@R76]).

Although it has been accepted that the RPE is the major pathogenic target of macular degeneration, obtaining a sufficient number of RPE cells from suitable donors for disease modeling remains an obstacle. The ARPE19 cell line derived from human RPE cells, is the most widely employed *in vitro* model for studying RPE function; however, there has been a lack of consistency in the results generated in these cells as ARPE19 cells do not truly recapitulate the characteristics of human RPE cells. ARPE19 cells express low levels of several RPE markers, are unable to metabolize vitamin A and have a reduced capacity to express critical proteins which regulate and maintain tight junctions ([@R2], [@R23]). Development of better RPE cell models for studying human diseases is in critical need.

Pluripotent stem cell (iPSC) technology has opened up a new era in disease modeling *via* providing the ability to differentiate adult somatic cells into any cell type in the body. iPSCs reprogrammed from adult somatic cells have an exciting potential in human disease modeling as well as cell sources for regenerative medicine. For example, iPSCs which are derived from skin or blood cells can be reprogrammed into beta islet cells to treat diabetes, blood cells to create new blood, or neurons to treat neurological disorders ([@R100], [@R92], [@R101], [@R61]). Several research groups have utilized iPSCs to differentiate into RPE-like cells with striking similarities to native RPE cells ([@R16], [@R14], [@R55], [@R63]). RPE cells derived from iPSCs are analogous to human fetal RPE cells with respect to expression of key RPE markers and display RPE functionalities such as formation of tight junctions, protein secretion, phagocytosis and vitamin A metabolism ([@R19]). hiPSC-RPE cells have met standards for use in clinical trials and transplantation therapies have been conducted in patients with eye diseases ([@R78], [@R59]). hiPSCs provide access to physiologically relevant samples without the issues associated with paucity of adequate primary human RPE tissues and their limited proliferation potential.

In the current study, we isolated peripheral blood mononuclear cells from healthy donors, reprogrammed them to iPSCs followed by differentiation to RPE cells. hiPSC-RPE displayed all features akin to functionally normal RPE cells *in vivo* including morphology, monolayers and tight junction formation, secretory function and ability to carry out phagocytosis. Exposure to physiological stressors such as A2E and H~2~O~2~ mimicked distinct phenotypes of pathologic or aged RPE cells with inflammation and decrease in cell viability. Our study provides a unique experimental platform not only to understand distinct aspects of RPE function but also to dissect the complex cellular and molecular events in degenerative retinal diseases.

2. Materials and methods {#S2}
========================

2.1. Generation of human iPSCs {#S3}
------------------------------

Blood samples were collected from healthy volunteers and peripheral blood mononuclear cells (PBMCs) were isolated using BD Vacutainer Cell Preparation Tubes containing sodium citrate. PBMCs were expanded and transduced with STEMCCA lentivirus vector using an earlier published protocol ([@R84]). iPSC-like colonies were picked and maintained up to passage 10 on Matrigel (Corning Bioscience, USA) coated plates. After each passage differentiated cells were discarded and only iPSC-like colonies were propagated. After passage 10, iPSC-like colonies were tested for expression of pluripotency markers *via* quantitative RT-PCR and immunocytochemistry. All procedures were approved by the Institutional Review Boards (IRBs) at the Case Western Reserve University, Cleveland Ohio and adhered to the Declaration of Helsinki. All cell culture procedures were approved by Case Western Reserve University Institutional Biosafety Committee. All samples were obtained after patients had given informed consent.

2.2. Differentiation of human iPSCs to RPE cells {#S4}
------------------------------------------------

Fully characterized iPSC lines at passage 10 were used for differentiation. iPSCs were differentiated to functional RPE using a previously reported protocol ([@R63], [@R64]). Briefly, cells were plated on gelatin coated dish with an inhibitor cocktail of CKI7 (Casein Kinase 1 Inhibitor) (Sigma, St. Lois, MO), SB431542 (Sigma) and ROCKi (Stemcell Technologies, Vancouver, Canada) in ReproCELL ReproStem Cell Culture medium (Stemgent Inc., MA) for one day. Culture medium was replaced by RPE differentiation medium with 20% KSR (ThermoFisher Scientific, MA) on day 1 and 3. On day 5, 7 and 9, KSR was reduced to 15% followed by 10% KSR from day 11 to day 18. Inhibitor cocktail was added up to day 18. Day 19 onwards cells were grown in 10% KSR until dark colonies appeared. Around day 30--35, when dark pigmented colonies appeared, cells were maintained in RPE maintenance medium. Around 10 days later, cells were detached and allowed to float as aggregates for 5 days to 2 weeks. Dark pigmented aggregates were then plated on CellStar coated plates (ThermoFisher Scientific, MA). After cells expanded, non-RPE cells were scrapped off manually and cells showing RPE morphology and pigmentation were passaged. RPE cells were allowed to mature for 30 days in RPE maintenance medium with bFGF (Stemcell Technologies) and SB431542 before being used for experiments.

2.3. RPE monolayers {#S5}
-------------------

RPE monolayers were established on 8 well chamber slides ([@R63], [@R64], Germany) or 96 well plates coated with CellStart for 30 days. 30,000--50,000 cells were seeded in each well from passage 4. Primary human RPE cells were obtained from Lonza (Walkersville, MD) and cultured in RPE maintenance medium. After the cells were attached medium was replaced every 2--3 days. At least 5 independent monolayers of cells were grown for each experiment.

### 2.3.1. Immunocytochemistry {#S6}

Cells were washed once in PBS, and fixed in 4% paraformaldehyde solution (Electron Microscopy Sciences, Hatfield, PA) for 15 min. Cells were washed three times in PBS at room temperature and permeabilized by exposure to 1% Triton X-100 (Sigma, St. Lois, MO) for 1 min at room temperature. Samples were washed three times in PBS at room temperature and blocked with 1% goat serum for 45 min followed by incubation with primary antibodies (TRA-1-60, 1:50, SSEA4, 1:50, SSEA1, 1:50, OCT-4, 1; 50, EMD Millipore, MA), RPE65 antibody (1:250) ([@R30]) and rabbit anti-ZO-1 antibody (1:200, Invitrogen) for 1 h at room temperature. The cells were washed three times in PBS, and incubated with secondary antibodies (Alexa Fluor 488 goat anti-rabbit or Alexa Fluor 555 goat anti-mouse IgG (1:500; Invitrogen) for 30 min at room temperature followed by PBS wash three times for 5 min. DAPI (4′,6-diamidino-2-phenylindole) (Molecular Probes, Eugene, OR) was used to stain nuclei. Cells were visualized and imaged under an inverted fluorescence microscope.

### 2.3.2. RT-PCR and qRT-PCR {#S7}

Total RNA was extracted with the RNeasy kit (Qiagen, Valencia, CA), treated with RNase-free DNAase I (Qiagen) and reverse transcribed using the cDNA synthesis kit (Qiagen) as previously described ([@R75], [@R67]). PCR was performed using gene specific primer sequences designed using web tool Primer 3 and synthesized by Eurofins MWG Operon (Hunstville, Al). The PCR products were separated by electrophoresis on a 1% agarose gel and detected under UV illumination. Quantitative RT-PCR was performed with SYBR® Green Supermix (Bio-Rad, Hercules, CA) on the Light cycler 96 Real-Time PCR system (Roche Diagnostics, Risch-Rotkreuz, Switzerland). Relative expression of genes was normalized to the housekeeping gene *Gapdh*. Primers used for this study are listed in [Table 1](#T1){ref-type="table"}.

### 2.3.3. Enzyme-Linked Immunosorbent Assay (ELISA) {#S8}

Production of VEGF-A, PEDF and IL6 was quantified by ELISA kits (VEGF-A; VEGF-A Quantikine ELISA kit (R&D Systems, Minneapolis, USA), PEDF; PEDF613, BioProducts (MD, USA), IL6; IL6 Quantikine ELISA kit (R&D Systems). For VEGF-A and PEDF measurements 50 μl of culture supernatant was collected and spun down at 10,000 rpm for 10 min. The clear supernatant collected was used for protein quantification. Cell lysates were prepared with Nonidet P-40 lysis buffer containing 20 mM Tris, pH 8.0, 137 mM NaCl, and 1% Nonidet P-40. Protein concentration was measured with a BCA protein assay kit (Pierce, MA, USA). Triplicate wells were used for all conditions tested.

### 2.3.4. Phagocytosis assay {#S9}

Cells were cultured at a density of 10^5^ cells/cm^2^ in RPE maintenance medium. On the day of the assay cell medium was removed and 100 μl of pHrodo^™^ BioParticles® (Molecular Probes) conjugate was added to the 96 well plate. Cell density was scaled at 10^6^ cells for 1 vial of 100 μl of the bead conjugate. The cells were then incubated at 37 °C for 2 h, 6 h and 24 h. After incubation, the cells were washed three times with PBS to remove the undigested beads. Cells were then fixed with 4% paraformaldehyde for 15 min followed by three washes with PBS. For imaging the cells were counterstained using DAPI and observed with an inverted fluorescence microscope (Leica, Wetzlar, Germany). The average fluorescent intensity per cell was measured on SpectaMax Plus 384 microplate reader (Molecular devices, Sunnyvale, CA) at 509/533 nm. The average fluorescence value of control wells with no beads is subtracted from wells containing beads at the end of the assay to yield a cell-specific, net phagocytosis signal. Each assay was repeated three times.

### 2.3.5. Cell death assay {#S10}

Cell death was assessed using LDH-Cytotoxicity Colorimetric Assay Kit II (BioVision, Milpitas, CA) following manufacturer's instructions. Cells were cultured in 96 well plates at a density of 10^4^ cells/well at 37 °C. Activity of lactate dehydrogenase (LDH) released from dead cells into the culture supernatants was measured at 450 nm wavelength with a microplate reader (Multiscan FC Microplate Reader, Fisher Scientific Inc., Pittsburgh, PA). The percentage cytotoxicity was calculated as \[(test sample -- cell negative control)/(lysis control -- cell negative control)\] × 100.

### 2.3.6. A2E treatment {#S11}

Cells were grown to 95--100% confluency in 96-well plates, at 37 °C with 5% O~2~ and 5% CO~2.~ A2E was purified according to method published earlier ([@R66]). Stock A2E solution (40 mM in DMSO) was diluted to a final concentration of 1--100 μM in prewarmed RPE maintenance medium and added to the plates, as specified. Manipulations involving A2E (and vehicle) addition, and all medium changes and feedings were conducted under dim (60--65 lx) light. For the repeated A2E feeding procedure, media containing A2E (10 μM) was replaced for 4 days and culture supernatant was collected.

### 2.3.7. H~2~O~2~ treatment {#S12}

Cells were grown to 95--100% confluency in 96-well plates, at 37 °C with 5% O~2~ and 5% CO~2.~ Cells were treated with 100 μM H~2~O~2~ for 4 days. Fresh H~2~O~2~ was added and culture supernatant was collected every 24 h.

### 2.3.8. RT^2^ profiler PCR Array {#S13}

Quantitative mRNA expression analysis of inflammatory chemokines and cytokines was performed using Pathway-Focused gene expression profiling using Light cycler\@96 Real-time PCR system (Roche). Total RNA was isolated using RNeasy kit (Qiagen), reverse transcribed using the cDNA synthesis kit (Qiagen) as previously described. cDNA from each experimental condition was used to run PCR array analysis according to the manufacturer's protocol with the RT^2^ SYBR® master mix (ThermoFisher scientific). mRNA expression of each gene was normalized using the expression of multiple housekeeping genes. Average normalization was applied to the data and the expression signals were converted to log2 scale for analysis. Data analysis was performed using Excel macro provided with the kit and Gene Set Enrichment Analysis (GSEA) software ([@R90]).

2.4. Statistical analysis {#S14}
-------------------------

The results were presented as mean ± SD. Statistical analyses were performed using the *t*-test for comparing 2 groups, and one-way ANOVA was used to detect differences among 3 or more groups. The results were considered statistically significant at *P* \< 0.05.

3. Results {#S15}
==========

3.1. Generation and characterization of iPSC from healthy donor blood {#S16}
---------------------------------------------------------------------

Peripheral blood mononuclear cells (PBMCs) isolated from healthy donors with no known history of retinal pathology were expanded for 9 days. On day 9, PBMCs were transduced with STEMCCA lentiviral vector encoding reprogramming factors Oct4, Klf4, Sox2 and c-Myc. Transduced PBMCs on day 15 showed change in morphology from round circular to more elongated shape. Around day 30, fully formed hiPSC-like colonies became visible ([Fig. 1A--C](#F1){ref-type="fig"}). hiPSC-like colonies were picked and passaged manually for 10 times. With each passaging step, differentiated cells were excluded and only undifferentiated colonies were propagated. After passage 10, expression of pluripotency marker genes *Oct4*, *Sox2*, *Rex1* and *Nanog* was detected ([Fig. 1D](#F1){ref-type="fig"}). hiPSC-like colonies displayed positive immunostaining for stem cell markers including SSEA4, TRA1-60 and TRA1-81 ([Fig. 1E--G](#F1){ref-type="fig"}). hiPSC colonies also stained positive for alkaline phosphatase ([Fig. 1H](#F1){ref-type="fig"}). These results indicate that hiPSC lines generated in this study are pluripotent.

3.2. Characterization of RPE cells differentiated from hiPSC {#S17}
------------------------------------------------------------

hiPSC lines from a healthy donor were used for RPE differentiation. Differentiated hiPSC-RPE cells displayed tightly packed pigmented and polygonal cells ([Fig. 2A](#F2){ref-type="fig"}). RPE65, a crucial gene for RPE function was expressed abundantly in hiPSC-RPE cells ([Fig. 2B](#F2){ref-type="fig"}). ZO-1 expression was detected by immunocytochemistry indicating that tight junctions are intact in the RPE monolayer ([Fig. 2C](#F2){ref-type="fig"}). Expression of RPE-specific genes *RPE65*, *MITF*, *BEST1*, *MERTK*, *PAX6*, and *TYR1* was detected by qRT-PCR ([Fig. 2D](#F2){ref-type="fig"}). Expression of these markers was weakly or not detected in undifferentiated hiPSC lines. To confirm the functionality of hiPSC-RPE cells, their ability of phagocytosis and secretion of cytokines was examined. Phagocytosis ability of hiPSC-RPE cells was measured as a function of time by incubation with pHrodo® beads. Internalization of beads by hiPSC-RPE cells markedly increased at 24 h, indicating that hiPSC-RPE cells possess phagocytosis ability ([Fig. 2E, F](#F2){ref-type="fig"}). Secretion of VEGF-A and PEDF from RPE cells was investigated by measuring amounts of these proteins in the culture supernatants when RPE cells were plated as a monolayer. Higher VEGF-A secretion in hiPSC-RPE cells than that of human primary RPE cells was documented and similar PEDF production was observed among hiPSC-RPE cells and human primary RPE cells ([Fig. 3A, 3B](#F3){ref-type="fig"}). These data demonstrated successful differentiation of hiPSC lines into pigmented cells with typical RPE characteristics.

3.3. A2E causes cell death in hiPSC-RPE cells {#S18}
---------------------------------------------

A2E accumulation in RPE cells is a hallmark of Stargardt disease and AMD ([@R85]). To examine effects of A2E in RPE cells, hiPSC-RPE cells were co-incubated with 10 μM of A2E for 4 days, which can achieve a physiological concentration of A2E in human RPE cells ([@R86]). Fresh A2E was replaced in the culture medium every day for 4 days. Light microscopy revealed co-incubation with A2E increased the number of round-shaped cells as compared to the untreated cells ([Fig. 4A, B](#F4){ref-type="fig"}). Upon immunostaining with a tight junction protein ZO-1, decreased numbers of regular polygonal shape of the RPE with enlarged cellular size (65.56 ± 9.27 μm *vs* 24.88 ± 3.51 μm, A2E-treated *vs* untreated) was observed, indicating that A2E led to disruption of tight junctions, loss of RPE monolayer integrity and decreased cell numbers as compared to untreated cells ([Fig. 4C, D](#F4){ref-type="fig"}). Indeed, cell death assay by measuring lactate dehydrogenase (LDH) in the culture supernatants revealed a dose- and time-dependent increase in cell death when hiPSC-RPE cells were cultured with A2E ([Fig. 4E, F](#F4){ref-type="fig"}, [Supplemental Fig. 1](#SD1){ref-type="supplementary-material"}). Increased IL6 and VEGF-A secretion was also observed in a dose- and time-dependent fashion ([Fig. 4F](#F4){ref-type="fig"}, [Supplemental Fig. 2](#SD1){ref-type="supplementary-material"}).

3.4. A2E can cause inflammatory changes in hiPSC-RPE cells {#S19}
----------------------------------------------------------

Previous studies have reported inflammatory changes caused by A2E ([@R71], [@R8]). Therefore, we examined if A2E can elicit inflammatory changes by employing RNA array profiling of 84 human chemokines and cytokines in hiPSC-RPE cells treated with 10 μM of A2E for 4 days. Chemokine and cytokine expression was compared between the treated and untreated cells. Applying a 2-fold cut-off, 26 cytokines were found upregulated as listed in [Table 2](#T2){ref-type="table"}. Scatter plot shows the changes of some of these upregulated genes ([Fig. 5A](#F5){ref-type="fig"}). Genes found upregulated were uploaded in GSEA (Gene set enrichment analysis software) databa. Annotated gene sets contain genes classified according to their *GO* biological processes. Six major biological pathways were found upregulated besides inflammation including interleukin signaling, TGFβ signaling, VEGF signaling, Apoptosis and Angiogenesis pathways ([Fig. 5B](#F5){ref-type="fig"}). Two-fold or more upregulation of *CXCL12*, *IL23A*, *TGFB2*, *CXCL1*, *IL16*, *CCL2*, *IL1B* and *CXCL8* was validated by qRT-PCR ([Fig. 5C](#F5){ref-type="fig"}). IL6 protein levels were found upregulated as measured by ELISA ([Fig. 5D](#F5){ref-type="fig"}). These observations provide evidence that A2E can cause inflammatory changes which are observed in retinal degenerative diseases including AMD ([@R15], [@R7], [@R49]). To investigate further if A2E can lead to any changes in the AMD-associated genes which were not included in the RNA array, qRT-PCR of *C2*, *C3*, *C5*, *CFH*, *TIMP1*, *TIMP3*, *MMP9*, *SERPINA3*, *APOE*, *TNFSF10*, *LIPC* and *ABCA4* was performed with A2E-treated hiPSC-RPE cells. These genes have been reported as AMD-associated genes based on the genome-wide association studies (GWAS) with AMD subjects ([@R28]). Complement proteins *C2*, *C3* and *CFH* were upregulated, while *C5* was unchanged. Other genes *TIMP1*, *TIMP3*, *MMP9*, *SERPINA3*, *APOE* and *ABCA4* were also upregulated, while *TNFSF10* and *LIPC* were unchanged ([Fig. 5E](#F5){ref-type="fig"}).

3.5. Oxidative stress with H~2~O~2~ causes significant upregulation of inflammatory cytokines in hiPSC-RPE cells {#S20}
----------------------------------------------------------------------------------------------------------------

Photooxidation of A2E generates oxidative stress, which can be one of the major contributors to the pathogenesis of retinal diseases ([@R88], [@R103], [@R18], [@R8], [@R87], [@R77], [@R74], [@R66]). To investigate if oxidative stress can recapitulate A2E-associated changes, hiPSC-RPE cells were exposed to 100 μM of H~2~O~2~ for 4 days. RNA array profiling of 84 human chemokines and cytokines using qRT-PCR was also carried out with treated and untreated cells. Applying a 2-fold cut-off, expression of 12 cytokines were found upregulated. qRT-PCR validation of *CXCL1*, *IL11*, *IL6*, *IL7*, *CXCL8*, *TNFSF10* and *TNFSF13B* showed 2-fold or more upregulation ([Fig. 6A](#F6){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). Secreted levels of IL6 protein increased with H~2~O~2~ treatment as measured by ELISA ([Fig. 6B](#F6){ref-type="fig"}). To investigate changes in AMD-associated genes with H~2~O~2~ treatment, qRT-PCR of *C2*, *C3*, *C5*, *CFH*, *TIMP1*, *TIMP3*, *MMP9*, *SERPINA3*, *APOE*, *TNFSF10*, *LIPC* and *ABCA4* was performed. *TIMP3* was upregulated 3-fold while no significant increase was observed in any of the other drusen/AMD-associated genes ([Fig. 6C](#F6){ref-type="fig"}). Upon comparing the results from array analyses with A2E and H~2~O~2~ stressed hiPSC-RPE cells, 9 genes *CXCL1*, *IL11*, *IL6*, *CXCL8*, *TNFSF10*, *IL7*, *TNFRSF11B* and *IL23A* and CSF1 were found to be common while 3 genes were exclusive to H~2~O~2~ induced stress namely CSF3, *CXCL11*, and *TNFSF13B* ([Fig. 7](#F7){ref-type="fig"}). Notably, A2E-treated hiPSC-RPE cells displayed similar inflammatory changes documented in AMD, whereas H~2~O~2~ treated hiPSC-RPE cells displayed minimal inflammatory changes.

4. Discussion {#S21}
=============

Dysfunction or death of RPE cells underlies pathogenesis of retinal degenerative disorders including Stargardt disease and AMD. The complex functional alterations and phenotypes in diseased RPE cells are still not completely understood. hiPSCs have emerged as a powerful tool for human disease modeling to study pathophysiology as wells as for therapeutic development such as drug screening and cell-based transplantation therapy ([@R11], [@R37], [@R46], [@R51], [@R14], [@R22]). RPE cells and other ocular cells are of particular interest because they are applicable for treating degenerative eye diseases ([@R59]). We employed iPSC technology to differentiate hiPSCs from blood of healthy donors to RPE cells. hiPSCs derived from PBMCs were successfully differentiated into RPE cells. This successful RPE differentiation was confirmed by morphology, cytokine secretion, and ability of phagocytosis. First, hiPSC-RPE cells displayed a typical hexagonal/cobblestone morphology with pigmentation which is unique for human RPE cells. This unique feature of RPE cells can serve an important indicator for cell identity ([@R14], [@R81]). One essential characteristic of RPE cells is the formation of tight junctions. Immunofluorescent staining for the tight junction protein, ZO-1, showed continuous junctions between hexagonal RPE cells. The tight junctions dynamically interact with numerous other proteins to regulate the paracellular permeability, the polar orientation of the membrane proteins, and protein expression ([@R17], [@R104], [@R2]). hiPSC-RPE cells in this study also successfully expressed RPE gene transcripts similar to human primary RPE cells.

Secretion properties which are characteristic for native RPE and hiPSC-RPE cells underlie the capacity of hiPSC-RPE cells to form functional, polarized monolayers ([@R13], [@R2], [@R81]). In accordance with the previous findings, we documented hiPSC-RPE cells to secrete high levels of VEGF-A in levels comparable to human primary RPE cells. VEGF-A is associated with formation of choroidal neovascularization and it is the principle cytokine responsible for neovascularization in the matured eye ([@R32], [@R96]). hiPSC-RPE cells also secreted high levels of Pigment-epithelium-derived-factor (PEDF) comparable to human primary RPE cells. PEDF is known to be secreted in large quantities by the native RPE and is an important antagonist that limits the mitogenic activity of VEGF-A ([@R96]).

Phagocytosis is another key function of RPE cells ([@R89]). Internalization of pHrodo® beads by immunofluorescence was observed in hiPSC-RPE cells verifying the phagocytotic properties of these cells. Collectively, all of these results suggest that the current methodologies for iPSC establishment and RPE differentiation can produce physiologically functional hiPSC-RPE cells *in vitro*.

hiPSC-RPE cells were then used to examine how A2E can affect these human cells. Previous research and clinical observation implicate noxious roles of A2E to RPE cells ([@R95], [@R68], [@R27], [@R86], [@R85]); however, a mouse model with A2E accumulation only shows a mild phenotype ([@R99], [@R97]). Difficulty in studying the formation and consequences of lipofuscin granules in RPE cell culture is compounded by the fact that these pigment granules do not normally occur in established RPE cell lines and pigment granules are rapidly lost in adult human primary culture ([@R12], [@R26], [@R38]). It is still not clear as to what cellular events are mediated by A2E, which ultimately lead to RPE damage and retinal degeneration in humans. Exposure to a physiological concentration of A2E ([@R86]) successfully mimicked distinct cellular disease phenotypes demonstrated by disrupted cell morphology, decreased epithelial integrity, increase in cell death and increased inflammation. A dose- and time-dependent A2E effect was also documented in hiPSC-RPE cells. Additionally, A2E treatment caused an increase in VEGF-A secretion, suggesting breakdown of barrier integrity. VEGF family of proteins are potent modulators of barrier function in both retinal endothelia and the RPE ([@R1], [@R21]). VEGF proteins can increase endothelial permeability and proliferation and are an important factor in retinal degeneration, particularly AMD pathogenesis ([@R29], [@R6], [@R83]). Treatments, including pegaptanib, ranibizumab, and bevacizumab, block the effects of VEGF-A and constitute the main pharmacological tools against neovascular AMD (or also called wet AMD) ([@R80], [@R39], [@R50]). Few studies have used anti-VEGF therapies to reduce neovascularization in patients with Stargardt disease ([@R9], [@R69]).

RNA array analyses of A2E-treated RPE cells revealed upregulation of 26 pro-inflammatory cytokines. IL-6 and IL-8 pro-inflammatory genotypes are reportedly associated to AMD pathobiology ([@R73], [@R79], [@R31]). These interleukins are increased in the aqueous humor of patients with wet AMD and their concentrations have been correlated with retinal neovascular activity and the volume of macular edema ([@R82], [@R8]). Although progression from inflammation to pathogenesis of Stargardt disease has been experimentally suggested ([@R71], [@R54]) there is limited information available for changes in inflammatory genes in patients with Stargardt disease. Of note increased expression of several AMD-associated proteins by A2E was documented, implying the potential of hiPSC-RPE cells as a powerful *in vitro* model of AMD. Additionally, after identification that *CFH* Y402H variant is associated with AMD in 2005, complement regulatory protein is considered as a major risk factor for developing AMD ([@R53], [@R24], [@R35], [@R34], [@R102]). This discovery has also suggested that inflammation can be an important contribution to AMD pathogenesis. Recent GWAS have also identified approximately 20 AMD-associated genetic variants, several of which have been localized to complement component genes, including *CFH*, *CFI*, *CFB*, and *C3* ([@R93]). These studies have implicated that dysfunctional RPE cells lead to secretion of several proteins of the complement-associated pathway, including TIMP3, APOJ, annexin, crystallins, APOE, vitronectin, and amyloid β ([@R70], [@R43]). In addition to AMD, the most recent study also revealed that complement modulation in RPE cells can reduce disease phenotypes in a mouse model of Stargardt disease, and accumulating information indicates complement roles in Stargardt disease as well as AMD ([@R56]). Our current study provided evidence that A2E-treated hiPSC-RPE cells facilitate the secretion of these complement-associated proteins which are associated with AMD and Stargardt disease.

Oxidative stress could be an important factor in contributing to the development of retinal degeneration ([@R98], [@R36], [@R10], [@R44]). RPE cells are highly exposed to oxidative stress due to high rate of metabolism, exposure to scattered light, lipofuscin content, and hypoxia, all of which result in the generation of reactive oxygen species (ROS) ([@R45], [@R47], [@R72]). Several studies have reported that lowered expression of anti-oxidative enzymes such as SOD1, catalase and heme oxygenase 1 in the RPE, correlating with age or with incident AMD ([@R33], [@R48], [@R40]). In the current study, hiPSC-RPE cells subjected to oxidative stress by H~2~O~2~ exposure showed an increase in inflammatory responses. RNA array analyses of H~2~O~2~-treated RPE cells identified an upregulation of 12 pro-inflammatory cytokines. Interestingly, only *TIMP3* was found increased up to 3-fold while no significant increase was observed in any of the other AMD-associated genes, in contrast to that all of 11 genes except *C5* were increased in A2E-treated hiPSC-RPE cells. Notably A2E treatment of hiPSC-RPE cells recapitulates the dynamic changes in disease progression better as compared to H~2~O~2~ treatment.

5. Conclusions {#S22}
==============

In summary, our results demonstrate the successful reprogramming of human blood cells to iPSCs which can be further differentiated to RPE cells with structural and functional capabilities characteristic for native RPE cells. Employment of these hiPSC-RPE cells provides clear evidence that A2E plays an important role in pathogenesis of retinal diseases by causing RPE cell death and activating immune systems.
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![hiPSCs were generated from healthy donor blood. (A) PBMCs during expansion at day 9. (B) PBMCs after transduction with Lentiviral vector expressing Oct4, Klf4, Sox2 and c-Myc at day 15. (C) At around day 30, fully formed iPSC-like colonies appear. (D) Pluripotency specific gene expression for *Oct4*, *Sox2*, *Rex1* and *Nanog* was checked by qRT-PCR. (E--H) Pluripotency is confirmed by immunocytochemistry with SSEA4, TRA-1-60, TRA1-81 (green) and alkaline phosphatase staining (red). Scale bar in A, B and H represents 500 μm and in E, F and G represents 100 μm.](nihms949547f1){#F1}

![Differentiated RPE cells display RPE-specific features. (A) Morphology of RPE cells differentiated from hiPSC lines is shown by light microscopy. (B, C) RPE65 (green) and ZO-1 (red) immunocytochemistry shows localization in hiPSC-RPE cells. Nuclei were stained with DAPI (blue). (D) qRT-PCR gene expression analysis shows relative gene expression of *RPE65*, *MITF*, *BEST1*, *MERTK*, *PAX6* and *TYR1* normalized to *GAPDH*. (E) Phagocytosis ability of hiPSC-RPE cells is demonstrated by ingestion of beads (green) and immunostaining with ZO-1 (red). (F) Average fluorescence measured over time is shown. Bars indicate mean ± S.D. Scale bars represent 100 μm.](nihms949547f2){#F2}

![iPSC-RPE cells maintain RPE protein secretions. (A, B) Protein quantification by ELISA shows VEGF-A and PEDF levels in hiPSC-RPE and human RPE cells. Mean ± S.D. of individual wells is indicated.](nihms949547f3){#F3}

![A2E causes cell death and disruption of cell barrier integrity in iPSC-RPE cells. (A, B) Phase micrographs of A2E treated hiPSC-RPE cells compared to untreated cells. (C, D) Immunocytochemistry for ZO-1 (red) in A2E treated and untreated hiPSC-RPE cells. Cells are counterstained with DAPI (blue). Quantification of average cell diameters is presented here. (E) A2E induced cytotoxicity at different concentration was measured by LDH assay in A2E treated hiPSC-RPE cells after 24 h. (F) Cytotoxicity (in black) and VEGF-A (in grey) levels were measured by ELISA in hiPSC-RPE cells treated with A2E for four days. Bars indicate mean ± S.D. Scale bars indicate 100 μm.](nihms949547f4){#F4}

![Inflammatory changes are induced by A2E in iPSC-RPE cells. (A) RNA array analyses show the most highly upregulated cytokines and chemokines. (B) Pathway analysis by GSEA shows the most enriched biological pathways. (C) qRT-PCR analyses show cytokines significantly upregulated upon treatment with A2E. Fold changes against values obtained with A2E-untreated cells are presented. (D) Quantification of IL6 protein was carried out by ELISA. (E) qRT-PCR of AMD-associated genes in A2E treated hiPSC-RPE cells. Fold changes against values obtained with A2E-untreated cells are presented. Data are presented as the means ± S.D., *n* = 6. \**P* \< 0.05.](nihms949547f5){#F5}

![Oxidative stress with H~2~O~2~ causes significant upregulation of inflammatory cytokines in iPSC-RPE cells. (A) Validation by qRT-PCR analyses of cytokines upregulated by oxidative stress. Fold changes against values obtained with H~2~O~2~-untreated cells are presented. (B) Quantification of IL6 protein was carried out by ELISA. (C) qRT-PCR of AMD-associated genes in H~2~O~2~ treated hiPSC-RPE cells. Fold changes against values obtained with H~2~O~2~-untreated cells are presented.](nihms949547f6){#F6}

![A2E treatment induces more inflammatory and AMD-related changes than H~2~O~2~ treated iPSC-RPE cells. Venn diagram representing the key up-regulated cytokines in A2E and H~2~O~2~ treated hiPSC-RPE cells. BOLD indicates AMD-related genes.](nihms949547f7){#F7}

###### 

Human primer sequences used in the study.

  Gene         Primer sequence                  Position   Size   Accession no
  ------------ -------------------------------- ---------- ------ --------------
  *RPE65*      5′-CAATGGGTTTCTGATTGTGGA-3′      208        150    NM_000329
               5′-CCAGTTCTCACGTAAATTGGCTA-3′    59                
  *MITF*       5′-AGAGTCTGAAGCAAGAGCACTG-3′     224        145    NM_000248.3
               5′-TGCGGTCATTTATGTTAAATCTTC-3′   80                
  *BEST1*      5′-CATAGACACCAAAGACAAAAGC-3′     220        140    NM_001139443
               5′-GTGCTTCATCCCTGTTTTCC-3′       80                
  *MERTK*      5′-GTAAGGCTTGGCTTCTTCCC-3′       193        132    NM_006343
               5′-CCGTCCGGAGAGAAATTACA-3′       62                
  *PAX6*       5′-TCCGTTGGAACTGATGGAGT-3′       206        146    NM_000280
               5′-TAAGGATGTTGAACGGGCAG-3′       61                
  *TYR1*       5′-ACCATGTAGGATTCCCGGTT-3′       245        141    NM_000372
               5′-TGCCAACGATCCTATCTTCC-3′       105               
  *GAPDH*      5′-CCATCCACAGTCTTCTGGGT-3′       568        141    NM_002046
               5′-CCTCAAGATCATCAGCAAT-3′        427               
  *IL6*        5′-CTGCAGCCACTGGTTCTGT-3′        239        143    NM_000600
               5′-CCAGAGCTGTGCAGATGAGT-3′       97                
  *CXCL1*      5′-CTTCCTCCTCCCTTCTGGTC-3′       183        133    NM_001511
               5′-CCAAACCGAAGTCATAGCCA-3′       51                
  *CXCL12*     5′-GCCCTTCCCTAACACTGGTT-3′       232        135    NM_000609
               5′-TTGACCCGAAGCTAAAGTGG-3′       98                
  *IL11*       5′-GGGCGACAGCTGTATCTGG-3′        199        134    NM_000882.3
               5′-GGACAGGGAAGGGTTAAAGG-3′       66                
  *VEGFA*      5′-CACACAGGATGGCTTGAAGA-3′       265        136    NM_003376
               5′-AGGGCAGAATCATCACGAAG-3′       130               
  *C2*         5′-GATTCGAGGAGCAGCGATAG-3′       248        136    NM_000063
               5′-ATGTGGGATGGAGAAACAGC-3′       113               
  *C5*         5′-CCCTCCACAGCAGACATTTT-3′       178        148    NM_001735
               5′-TCAAGGCAAAGGTGTTCAAA-3′       31                
  *CFH*        5′-TTCGCTTTTTCTTTTAAGGCA-3′      234        133    NM_000186
               5′-CATGTATGGAGAATGGCTGG-3′       102               
  *TIMP3*      5′-GTACTGCACATGGGGCATCT-3′       279        149    NM_000362
               5′-AGGACGCCTTCTGCAACTC-3′        131               
  *MMP9*       5′-CTCAGGGCACTGCAGGAT-3′         262        133    NM_004994
               5′-CGACGTCTTCCAGTACCGA-3′        130               
  *SERPINA3*   5′-ATGGGCACCATTACCCACT-3′        234        140    NM_001085
               5′-ATGACTCCTTTCGCAGCCT-3′        95                
  *TIMP1*      5′-TTGACTTCTGGTGTCCCCAC-3′       197        137    NM_003254
               5′-GCTTCTGGCATCCTGTTGTT-3′       61                
  *IL23A*      5′-CCACACTGGATATGGGGAAC-3′       208        131    NM_016584
               5′-ACTCAGTGCCAGCAGCTTTC-3′       78                
  *TGFB2*      5′-CTCCATTGCTGAGACGTCAA-3′       222        133    NM_003238
               5′-CGACGAAGAGTACTACGCCA-3′       90                
  *CCL2*       5′-ATAACAGCAGGTGACTGGGG-3′       180        141    NM_002982
               5′-TCTCAAACTGAAGCTCGCAC-3′       40                
  *IL1B*       5′-GGAGATTCGTAGCTGGATGC-3′       209        144    NM_000576
               5′-GAGCTCGCCAGTGAAATGAT-3′       66                
  *CXCL8*      5′-AGCACTCCTTGGCAAAACTG-3′       172        137    NM_000584
               5′-CAAGAGCCAGGAAGAAACCA-3′       36                
  *C3*         5′-CCAGCTCTCTGGGAACTCAC-3′       217        144    NM_000064
               5′-TTCCTGGACTGCTGCAACTA-3′       74                
  *APOE*       5′-CAGGTAATCCCAAAAGCGAC-3′       247        144    NM_000041
               5′-TTGCTGGTCACATTCCTGG-3′        104               
  *TNFSF10*    5′-CTCTCTTCGTCATTGGGGTC-3′       232        139    NM_003810
               5′-TGCAGTCTCTCTGTGTGGCT-3′       94                
  *LIPC*       5′-CATCTCATGCAGCGTTTTGT-3′       200        133    NM_000236
               5′-TCCCCTGTGTTTCTCCATTC-3′       68                
  *ABCA4*      5′-TACTCGGCCGATGGATAAAC-3′       261        147    NM_000350
               5′-TGTATGCCAACGTGGACTTC-3′       115               
  *IL7*        5′-CGAGCAGCACGGAATAAAAA-3′       259        138    NM_000880
               5′-TCTAATGGTCAGCATCGATCA-3′      122               
  *TNFSF11B*   5′-TGAGATGAGCAAAAGGCTGA-3′       267        139    NM_033012
               5′-TTTCAAGGAGCTGTGCAAAA-3′       129               
  *OCT4*       5′-CTGGTTCGCTTTCTCTTTCG-3′       199        150    NM_203289
               5′-CTTTGAGGCTCTGCAGCTTA-3′       50                
  *SOX2*       5′-GGAAAGTTGGGATCGAACAA-3′       2215       145    NM_003106
               5′-GCGAACCATCTCTGTGGTCT-3′       2071              
  *REX1*       5′-TGCCTAGTGTGCTGGTGGT-3′        177        148    NM_174900
               5′-GGTGGCATTGGAAATAGCAG-3′       30                
  *NANOG*      5′-TTGGGACTGGTGGAAGAATC-3′       216        138    NM_024865
               5′-GATTTGTGGGCCTGAAGAAA-3′       79                
  *B-ACTIN*    5′-CCTTGCACATGCCGGAG-3′          127        127    NM_001101
               5′-GCACAGAGCCTCGCCTT-3′          16                

###### 

Upregulated genes (≥2.0 fold) after A2E treatment.

  Symbols       Gene names                                    Fold changes[a](#TFN1){ref-type="table-fn"}
  ------------- --------------------------------------------- ---------------------------------------------
  *CX3CL1*      C-X-C Motif Chemokine Ligand 1                2.1
  *BMP4*        Bone Morphogenetic Protein 4                  2.2
  *CXCL12*      C-X-C Motif Chemokine Ligand 12               2.2
  *IL11*        Interleukin 11                                2.4
  *IL1A*        Interleukin 1 Alpha                           2.5
  *CNTF*        Ciliary Neurotrophic Factor                   2.6
  *IL23A*       Interleukin 23 Subunit Alpha                  3.0
  *TNFRSF11B*   TNF Receptor Superfamily Member 11b           3.1
  *CXCL5*       C-X-C Motif Chemokine Ligand 5                3.1
  *CXCL16*      C-X-C Motif Chemokine ligand 16               3.4
  *GPI*         Glucose-6-Phosphate Isomerase                 3.8
  *LIF*         Leukemia Inhibitory Factor                    3.9
  *TGFB2*       Transforming Growth Factor Beta 2             4.2
  *IL7*         Interleukin 7                                 4.5
  *CXCL2*       C-X-C Motif Chemokine Ligand 2                4.6
  *CXCL1*       C-X-C motif chemokine ligand 1                5.4
  *IL6*         Interleukin 6                                 5.6
  *VEGFA*       Vascular Endothelial Growth Factor A          5.6
  *CCL2*        C-C Motif Chemokine Ligand 2                  5.7
  *CCL20*       C-C Motif Chemokine Ligand 20                 6.3
  *SPP1*        Secreted Phosphoprotein 1                     6.94
  *IL1B*        Interleukin 1 Beta                            9.8
  *BMP2*        Bone Morphogenetic Protein 4                  12.0
  *CSF1*        Colony Stimulating Factor 1                   13.5
  *TNFSF10*     Tumor Necrosis Factor Superfamily Member 10   15.8
  *CXCL8*       C-X-C Motif Chemokine Ligand 8                16.0

Fold changes were calculated against values from non-treated cells.

###### 

Upregulated genes (≥ 2.0 fold) after H~2~O~2~ treatment.

  Symbols       Gene names                                     Fold changes[a](#TFN2){ref-type="table-fn"}
  ------------- ---------------------------------------------- ---------------------------------------------
  *CSF1*        Colony Stimulating Factor 1                    2.06
  *CXCL11*      C-X-C Motif Chemokine Ligand 11                2.13
  *CXCL1*       C-X-C motif chemokine ligand 1                 2.50
  *TNFSF10*     Tumor Necrosis Factor Superfamily Member 10    2.50
  *IL23A*       Interleukin 23 Subunit alpha                   2.98
  *TNFSF13B*    Tumor Necrosis Factor Superfamily Member 13B   3.3
  *IL7*         Interleukin 7                                  3.59
  *IL11*        Interleukin 11                                 4.15
  *CSF3*        Colony Stimulating Factor 1                    4.18
  *IL6*         Interleukin 6                                  4.45
  *TNFRSF11B*   Tumor Necrosis Factor Superfamily Member 11B   5.68
  *CXCL8*       C-X-C Motif Chemokine Ligand 8                 7.9

Fold changes were calculated against values from non-treated cells
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